XBI Fact Sheet


State Street SPDR S&P Biotech ETF

$140.18
close, Nov 20, 2026

Over the year to Nov 18, 2026, XBI returned +26.5% in total and charged 0.35% a year.

1-year total return	Expense ratio	Net assets	Net flow, last 5 trading days
+23.7% to Nov 20, 2026	**0.35%** a year	**$9.6bn** on Nov 19, 2026	**-$303m** daily basis to Nov 19, 2026

Growth of $10,000, 1 year



XBI **$12,645** +26.5% · IVV **$11,186** +11.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WINDOW	TOTAL RETURN
1 month	**-8.2%**
3 months	**-15.4%**
Year to date	**+15.1%**
1 year	**+23.7%**
3 years	**+95.9%**
5 years	**+15.7%**

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HOLDING	WEIGHT
MODERNA INC	**2.31%**
TG THERAPEUTICS INC	**1.87%**
BIOGEN INC	**1.84%**
GILEAD SCIENCES INC	**1.80%**
REGENERON PHARMACEUTICALS	**1.79%**
EXELIXIS INC	**1.77%**
ABBVIE INC	**1.77%**
SPYRE THERAPEUTICS INC	**1.76%**
INSMED INC	**1.76%**
AMGEN INC	**1.75%**

XBI top ten by weight, 18.4% of the fund, of its 165 equity positions, from the holdings published by its issuer for Nov 19, 2026.

Facts

Holds 165 stocks in biotech, 14% of its weight in S&P 500 companies · First traded Feb 6, 2006 · Benchmark Its own holdings, as of Nov 19, 2026

ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/xbi.